Improving patient outcomes with regorafenib for metastatic colorectal cancer - patient selection, dosing, patient education, prophylaxis, and management of adverse events
Regorafenib is the first tyrosine kinase inhibitor approved for metastatic colorectal cancer. In 2 phase III trials, regorafenib significantly improved progression-free and overall survival in patients who had been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemoth...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
May 12, 2015
|
| In: |
Oncology research and treatment
Year: 2015, Volume: 38, Issue: 6, Pages: 300-308 |
| ISSN: | 2296-5262 |
| DOI: | 10.1159/000382067 |
| Online Access: | Verlag, Volltext: http://dx.doi.org/10.1159/000382067 Verlag, Volltext: http://www.karger.com.ezproxy.medma.uni-heidelberg.de/Article/FullText/382067 
|
| Author Notes: | Ralf-Dieter Hofheinz, Dirk Arnold, Stefan Kubicka, Nicole Prasnikar, Arndt Vogel |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1566886945 | ||
| 003 | DE-627 | ||
| 005 | 20220814052642.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180105s2015 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1159/000382067 |2 doi | |
| 035 | |a (DE-627)1566886945 | ||
| 035 | |a (DE-576)496886940 | ||
| 035 | |a (DE-599)BSZ496886940 | ||
| 035 | |a (OCoLC)1340985646 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Hofheinz, Ralf-Dieter |d 1969- |e VerfasserIn |0 (DE-588)121917517 |0 (DE-627)08161876X |0 (DE-576)292991568 |4 aut | |
| 245 | 1 | 0 | |a Improving patient outcomes with regorafenib for metastatic colorectal cancer - patient selection, dosing, patient education, prophylaxis, and management of adverse events |c Ralf-Dieter Hofheinz, Dirk Arnold, Stefan Kubicka, Nicole Prasnikar, Arndt Vogel |
| 264 | 1 | |c May 12, 2015 | |
| 300 | |a 8 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 05.01.2018 | ||
| 520 | |a Regorafenib is the first tyrosine kinase inhibitor approved for metastatic colorectal cancer. In 2 phase III trials, regorafenib significantly improved progression-free and overall survival in patients who had been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-vascular endothelial growth factor therapy, and, if (K)RAS wild type, an anti-epidermal growth factor receptor therapy. Its safety profile is in line with other multikinase and/or tyrosine kinase inhibitors approved for different indications. Commonly reported adverse events specifically associated with regorafenib include hand-foot skin reaction and hypertension, whereas others such as fatigue, diarrhea, and liver dysfunction may occur during both targeted and cytotoxic treatments. These adverse events frequently occur within the first cycles of treatment, are transient, and decrease in incidence over time. Patient selection, education, and management, as well as close communication between oncologists or trained nurses and patients, are essential for prevention and mitigation of treatment toxicity as is rapid implementation of dose modifications and temporary discontinuations. Effective management of adverse events enables patients who are responding to stay on treatment for a substantial period of time and thereby receive the full benefit of regorafenib therapy. This review aims to provide guidance around prophylaxis and management of regorafenib-associated adverse events. | ||
| 773 | 0 | 8 | |i Enthalten in |t Oncology research and treatment |d Basel : Karger, 2014 |g 38(2015), 6, Seite 300-308 |h Online-Ressource |w (DE-627)776629611 |w (DE-600)2749752-5 |w (DE-576)400081660 |x 2296-5262 |7 nnas |a Improving patient outcomes with regorafenib for metastatic colorectal cancer - patient selection, dosing, patient education, prophylaxis, and management of adverse events |
| 773 | 1 | 8 | |g volume:38 |g year:2015 |g number:6 |g pages:300-308 |g extent:8 |a Improving patient outcomes with regorafenib for metastatic colorectal cancer - patient selection, dosing, patient education, prophylaxis, and management of adverse events |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1159/000382067 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u http://www.karger.com.ezproxy.medma.uni-heidelberg.de/Article/FullText/382067 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20180105 | ||
| 993 | |a Article | ||
| 994 | |a 2015 | ||
| 998 | |g 121917517 |a Hofheinz, Ralf-Dieter |m 121917517:Hofheinz, Ralf-Dieter |d 60000 |d 61200 |e 60000PH121917517 |e 61200PH121917517 |k 0/60000/ |k 1/60000/61200/ |p 1 |x j | ||
| 999 | |a KXP-PPN1566886945 |e 2991690828 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"name":{"displayForm":["Ralf-Dieter Hofheinz, Dirk Arnold, Stefan Kubicka, Nicole Prasnikar, Arndt Vogel"]},"physDesc":[{"extent":"8 S."}],"relHost":[{"origin":[{"dateIssuedDisp":"2014-","publisher":"Karger","dateIssuedKey":"2014","publisherPlace":"Basel"}],"pubHistory":["37.2014 -"],"part":{"year":"2015","text":"38(2015), 6, Seite 300-308","issue":"6","extent":"8","volume":"38","pages":"300-308"},"id":{"zdb":["2749752-5"],"eki":["776629611"],"issn":["2296-5262"]},"disp":"Improving patient outcomes with regorafenib for metastatic colorectal cancer - patient selection, dosing, patient education, prophylaxis, and management of adverse eventsOncology research and treatment","note":["Gesehen am 15.12.2023"],"title":[{"title_sort":"Oncology research and treatment","title":"Oncology research and treatment"}],"language":["eng"],"recId":"776629611","type":{"bibl":"periodical","media":"Online-Ressource"},"physDesc":[{"extent":"Online-Ressource"}]}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"recId":"1566886945","language":["eng"],"title":[{"title_sort":"Improving patient outcomes with regorafenib for metastatic colorectal cancer - patient selection, dosing, patient education, prophylaxis, and management of adverse events","title":"Improving patient outcomes with regorafenib for metastatic colorectal cancer - patient selection, dosing, patient education, prophylaxis, and management of adverse events"}],"person":[{"family":"Hofheinz","given":"Ralf-Dieter","role":"aut","display":"Hofheinz, Ralf-Dieter"}],"note":["Gesehen am 05.01.2018"],"id":{"eki":["1566886945"],"doi":["10.1159/000382067"]},"origin":[{"dateIssuedDisp":"May 12, 2015","dateIssuedKey":"2015"}]} | ||
| SRT | |a HOFHEINZRAIMPROVINGP1220 | ||